Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Compelling short-term upside driven by multiple recent catalysts including strong Q4 2025 sales beat, raised 2026 guidance, regulatory approvals for key drugs, advancing clinical pipeline with upcoming pivotal data, and solid technical momentum showing a 13% price rise over 21 days.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Strong Profitability ⢠Improving Liquidity ⢠Elevated Leverage BMY offers strong margins, cash flow, liquidity and dividend appeal, but substantial leverage and intangible exposure warrant balance-sheet caution.
Price Behavior
Key Price Behavior Insights: ⢠Lower highs ⢠Oversold momentum ⢠Key support Support Level: $62.80â$63.10 Resistance Level: $64.70 BMY remains bearish below its last-month average, but oversold RSI and $62.80â$63.10 support could spur a rebound; watch $64.70 resistance and avoid renewed downside if support breaks.
Sentiment & News
Key News Insights: ⢠Portfolio Transition ⢠Guidance Raised ⢠Patent Exposure Bristol Myers Squibb's newer brands, raised guidance, and promising pipeline support growth, but legacy-product erosion and Eliquis patent risk remain key overhangs.
AI Summary
BMY's strong cash flow, dividend, and newer-brand growth make it a credible portfolio-replacement story rather than a pure patent-cliff decline, but the investment hinges on whether launches can scale fast enough to offset looming Eliquis and Opdivo erosion while reducing leverage. Investors should favor confirmation of sustained new-brand growth and a break above $65.66, while treating pipeline upside as unproven until regulatory, manufacturing, and adoption milestones are met.
Description
Bristol-Myers Squibb is a global biopharmaceutical company that researches, develops, licenses, manufactures and markets medicines across oncology, hematology, cardiovascular, immunology, fibrosis, neuroscience and infectious disease. Its commercial portfolio includes oral and biologic therapies for cancer, cardiovascular and immune-mediated conditions, with widely used products such as Eliquis and Opdivo, and it sells through wholesalers, pharmacies, hospitals and government channels. Founded in 1887, the company is headquartered in New York, New York.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Feb 9 | Feb 16 | BMY | Bristol-Myers Squibb Company | Compelling short-term upside driven by multiple recent catalysts including strong Q4 2025 sales beat, raised 2026 guidance, regulatory approvals for key drugs, advancing clinical pipeline with upcoming pivotal data, and solid technical momentum showing a 13% price rise over 21 days. | Closed | -0.1% |
| Dec 23 | Dec 30 | BMY | Bristol-Myers Squibb Company | Bristol Myers Squibb (BMY) benefits from 17% Q3 portfolio growth, upcoming FDA review and clinical data catalysts, strong operational turnaround with positive earnings and cash flow, and sustained 17% stock gain over 21 days with technical momentum. Its diversified oncology portfolio and dividend appeal underpin a strong near-term growth case. | Closed | -0.1% |
| Dec 4 | Dec 11 | BMY | Bristol-Myers Squibb Company | Bristol Myers Squibb shows compelling near-term upside with strong Q3 revenue and raised guidance, notable clinical/regulatory catalysts (FDA Fast Track, Phase 3 trials), substantial debt reduction, and technical breakout signaling positive momentum. | Closed | -1.5% |